Lu AH69593

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

9 competitors in Narcolepsy

#DrugCompanyPhaseTrials

1

Biaxin

AbbVie

Approved

12

Romazicon

CConrado Roberto Hoffmann Filho

Approved

—3

E2086

Eisai

Phase 2

24

Xyrem

Jazz Pharmaceuticals

Preclinical

—5

Wakix

HHarmony Biosciences Management, Inc.

Preclinical

16

JZP441

Jazz Pharmaceuticals

Phase 1

17

Lu AH69593

Lundbeck

Phase 1

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Narcolepsy1 trial

Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants

Recruiting·Lundbeck·Phase 1·NCT07613710·104 enrolled

Unspecified1 trial

Interventional, Open-label, Fixed-sequence Crossover Trial Investigating the Effect of CYP3A4/5 Modulation on the Pharmacokinetics, Safety and Tolerability of Lu AH69593 and the Effect of Lu AH69593 on the Pharmacokinetics of a CYP3A4/5 Substrate in Healthy Participants

Not yet recruiting·Lundbeck·Phase 1·NCT07775261·46 enrolled

Details

Drug Info

Related News